Friday, September 10, 2021 6:00:15 PM
The FDA says they will look at additional data and HGEN is pinning their hopes on the Activ5 trial. HGEN's trial was for severe/critical patients, Activ5 is for moderate to critical. HGEN's primary endpoint is Ventilator-free Survival, Activ5's primary endpoint is Time to ventilation or death in subjects with a baseline score of 5 or 6. The inclusion of moderate would not be beneficial to HGEN at all. The only potential saving grace is that the control arm consists of remdesivir with placebo. That they use remdesivir only in patients above mild ensuring a death sentence for many is criminal.
Avant Technologies Engages Wired4Tech to Evaluate the Performance of Next Generation AI Server Technology • AVAI • May 23, 2024 8:00 AM
Branded Legacy, Inc. Unveils Collaboration with Celebrity Tattoo Artist Kat Tat for New Tattoo Aftercare Product • BLEG • May 22, 2024 8:30 AM
"Defo's Morning Briefing" Set to Debut for "GreenliteTV" • GRNL • May 21, 2024 2:28 PM
North Bay Resources Announces 50/50 JV at Fran Gold Project, British Columbia; Initiates NI 43-101 Resources Estimate and Bulk Sample • NBRI • May 21, 2024 9:07 AM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONGD • May 17, 2024 11:00 AM